RadNet Management, Inc Discussions - radRounds Radiology Network2024-03-29T15:21:04Zhttps://community.radrounds.com/group/radnetmanagementinc/forum?feed=yes&xn_auth=noAspirin cuts death risk after breast cancertag:community.radrounds.com,2010-02-17:1791588:Topic:622372010-02-17T21:20:00.737ZRadNet Management, Inc.https://community.radrounds.com/profile/RadNetManagementInc
WASHINGTON - Breast cancer survivors who take aspirin regularly may be less likely to die or have their cancer return, U.S. researchers reported Tuesday.<br />
<p></p>
<p class="textBodyBlack"><span id="byLine"></span> </p>
<p class="textBodyBlack">The study of more than 4,000 nurses showed that those who took aspirin — usually to prevent heart disease — had a 50 percent lower risk of dying from breast cancer and a 50 percent lower risk that the cancer would spread.…</p>
WASHINGTON - Breast cancer survivors who take aspirin regularly may be less likely to die or have their cancer return, U.S. researchers reported Tuesday.<br />
<p></p>
<p class="textBodyBlack"><span id="byLine"></span> </p>
<p class="textBodyBlack">The study of more than 4,000 nurses showed that those who took aspirin — usually to prevent heart disease — had a 50 percent lower risk of dying from breast cancer and a 50 percent lower risk that the cancer would spread.</p>
<p class="textBodyBlack"> </p>
<p class="textBodyBlack"><span id="byLine"></span>"This is the first study to find that aspirin can significantly reduce the risk of cancer spread and death for women who have been treated for early stage breast cancer, " said Dr. Michelle Holmes of Harvard Medical School, who led the study published in the Journal of Clinical Oncology.</p>
<p class="textBodyBlack"> </p>
<p class="textBodyBlack"><span id="byLine"></span>"If these findings are confirmed in other clinical trials, taking aspirin may become another simple, low-cost and relatively safe tool to help women with breast cancer live longer, healthier lives," Holmes added in a statement.</p>
<p class="textBodyBlack"> </p>
<p class="textBodyBlack"><span id="byLine"></span>Holmes and her team studied 4,164 female registered nurses taking part in the Nurses' Health Study, an ongoing analysis of a wide range of health issues.</p>
<p class="textBodyBlack"> </p>
<p class="textBodyBlack"><span id="byLine"></span>They started in 1976, looking at who took aspirin, watching for breast cancer and all causes of death until 2006.</p>
<p class="textBodyBlack"> </p>
<p class="textBodyBlack"><span id="byLine"></span>Over this time, 341 of the nurses died of breast cancer.</p>
<p class="textBodyBlack"> </p>
<p class="textBodyBlack"><span id="byLine"></span>Women who took aspirin two to five days a week had a 60 percent reduced risk of their cancer spreading and a 71 percent lower risk of breast cancer death. Six to seven aspirins a week lowered the risk of spread by 43 percent and the risk of breast cancer death by 64 percent.</p>
<p class="textBodyBlack"><span id="byLine"></span>Most of the women were taking low-dose aspirin to prevent heart attacks and stroke.</p>
<p class="textBodyBlack"> </p>
<p class="textBodyBlack"><span id="byLine"></span><b><strong>Ibuprofen and naproxen appear to lower risk too</strong></b></p>
<p class="textBodyBlack"><b><strong>
</strong></b>Other drugs in the same class as aspirin also apparently lowered the risks, too. These drugs, called non-steroidal inflammatory drugs or NSAIDs, include ibuprofen and naproxen but not acetaminophen, also known as paracetamol.</p>
<p class="textBodyBlack"> </p>
<p class="textBodyBlack"><span id="byLine"></span>But there was not enough data on these drugs to give a clear answer.</p>
<p class="textBodyBlack"> </p>
<p class="textBodyBlack"><span id="byLine"></span>The researchers said they are not sure how aspirin and other NSAIDS may affect tumors but it could be by lowering inflammation. Other studies have shown that aspirin and ibuprofen can lower colon cancer risk, for instance.</p>
<p class="textBodyBlack"> </p>
<p class="textBodyBlack"><span id="byLine"></span>"Aspirin has relatively benign adverse effects compared with cancer chemotherapeutic drugs and may also prevent colon cancer, cardiovascular disease, and stroke," the researchers wrote. It affected both estrogen-positive tumors and those not fueled by the hormone.</p>
<p class="textBodyBlack"> </p>
<p class="textBodyBlack"><span id="byLine"></span>Holmes' team stressed that patients should not take aspirin while undergoing radiation or chemotherapy because of the risk of side effects.</p>
<p class="textBodyBlack"> </p>
<p class="textBodyBlack"><span id="byLine"></span>And aspirin can cause stomach bleeding so it should not be taken without a doctor's supervision.</p>
<p class="textBodyBlack"> </p>
<div class="textBodyBlack"><i><em>Copyright 2010 Reuters.</em></i></div> Radiotherapy For Breast Cancer - Dosage Questionstag:community.radrounds.com,2010-02-08:1791588:Topic:618992010-02-08T20:07:03.762ZRadNet Management, Inc.https://community.radrounds.com/profile/RadNetManagementInc
Radiotherapy For Breast Cancer - Dosage Questions <br/><a href="http://blogs.myspace.com/index.cfm?fuseaction=blog.ListAll&bID=528727026">http://blogs.myspace.com/index.cfm?fuseaction=blog.ListAll&bID=528727026</a>
Radiotherapy For Breast Cancer - Dosage Questions <br/><a href="http://blogs.myspace.com/index.cfm?fuseaction=blog.ListAll&bID=528727026">http://blogs.myspace.com/index.cfm?fuseaction=blog.ListAll&bID=528727026</a> NeuroQuant: Reducing MRI Analysis Time from 100 Hours to Less than 10 Minutestag:community.radrounds.com,2009-12-28:1791588:Topic:597632009-12-28T21:19:43.672ZRadNet Management, Inc.https://community.radrounds.com/profile/RadNetManagementInc
<b>Breakthrough: Unmasking Early-Stage Alzheimer's Disease<br />
Reducing MRI Analysis Time from 100 Hours to Less than 10 Minutes</b><br />
<br />
--------------------------------------------------------------------------------<br />
<br />
“Debbie, have you seen my keys?”<br />
<br />
We all ask questions like that. In an active life, it’s easy to lose track of things when we’re distracted, in a hurry, or in multi-tasking overload.<br />
<br />
But mild forgetfulness, when it appears to be progressive, can have a different meaning for people in…
<b>Breakthrough: Unmasking Early-Stage Alzheimer's Disease<br />
Reducing MRI Analysis Time from 100 Hours to Less than 10 Minutes</b><br />
<br />
--------------------------------------------------------------------------------<br />
<br />
“Debbie, have you seen my keys?”<br />
<br />
We all ask questions like that. In an active life, it’s easy to lose track of things when we’re distracted, in a hurry, or in multi-tasking overload.<br />
<br />
But mild forgetfulness, when it appears to be progressive, can have a different meaning for people in their 60s, 70s, or 80s. It may stem from a variety of causes, including stress; but it can also be an early indicator of Alzheimer's disease (AD) or less common neurological problems. This sums up the challenge facing neurologists when they see a patient with what is known as mild cognitive impairment (MCI). How can they diagnose AD with a high degree of certainty in the early stages – when it may still be possible to arrest it?<br />
<br />
Professor James Brewer of the University of California at San Diego (UCSD) is doing groundbreaking work with a Mac-based diagnostic system known as NeuroQuant that automates analysis of magnetic resonance (MRI) images of the brain. He is the first physician to use this technology on a clinical basis to examine patients’ brains for the tell-tale effects of Alzheimer's disease.<br />
<br />
“Diagnosing Alzheimer’s may be helped by taking volume measurements of regions of the brain,” says Brewer. “The old way of doing this is unbelievably painstaking. The MRI is 256 slices with 256x256 resolution, so every voxel is about a millimeter in each direction. One used to have to flip through the MRI slice by slice and trace the hippocampi and other brain regions on each slice using a program called Amira. That could take even an expert neuroanatomist 100 hours.<br />
<br />
”Now I have a beautiful setup. The iMac sits on my desk and runs NeuroQuant, which processes an MRI and delivers a quantitative analysis of the entire brain structure in less than 10 minutes. This is a simple, powerful arrangement for doing both research and clinical practice.”<br />
<br />
Brewer’s work will be of intense interest to clinical neurologists – and to anyone whose loved one is facing memory loss.<br />
<br />
<b>The Tragedy of Patient HM: Life without Memory</b><br />
The mystery behind memory loss in AD began to unravel in Boston’s Hartford Hospital in 1957. A man known today as Patient HM came to the hospital suffering from severe epilepsy. He was 27 and unemployable, incapacitated by up to 11 seizures a day. Electroencephalography revealed that the source of the seizures was Patient HM’s hippocampi – a pair of seahorse-shaped organs not far from the inner ear. (“Put a fingertip in your ear,” says Brewer, “and it will be about an inch and a half from a hippocampus.”)<br />
<br />
The hospital offered Patient HM an experimental procedure with no guarantee of success: removal of part of his medial temporal lobes, including his hippocampi. Patient HM agreed, and the procedure worked. From that point on his seizures were reduced to about two a year. But there was an extraordinary side effect: from that day forward he formed no new memories of any event. He could acquire knowledge and skills, and his pre-operation memories were intact, but nothing that happened afterwards remained in his memory, including the death of his mother and the first moon landing. He described his condition as constantly waking up from a dream and wondering where he was. Word of his plight inspired production of the acclaimed 2000 movie Memento, which Brewer says portrayed the symptoms accurately. The hero was forced to tattoo himself to retain vital information.<br />
<br />
Once it became clear that the hippocampi are the gateways of episodic memory -- the memory of events – scientists were able to focus on them as the probable site of AD. Studies revealed that while the brain of a healthy person shrinks by nearly one percent per year, the hippocampi of an Alzheimer's patient shrinks at five times that rate.<br />
<br />
“We’ve known since the early 90s that the hippocampus starts shrinking very early in the development of Alzheimer's disease,” says Brewer. “There are variants of the disease, but they’re very atypical.”<br />
<br />
Today, with an aging US population and an increasing number of dementia patients, there’s a pressing need to apply this knowledge to clinical diagnosis. But neurologists have been severely technology-limited. What they need is a practical, quantified way to compare their patients’ hippocampi with the hippocampi of healthy people of the same age. MRI scans can deliver high-resolution DICOM-format image slices of a patient’s brain. But to manually quantify 256 hippocampi MRI image slices is, as Brewer points out, a mind-numbing, weeks-long job – an impossibility for routine diagnosis.<br />
<br />
<b>NeuroQuant: Automated, Mac-Based MRI Analysis</b><br />
When NeuroQuant receives a set of DICOM images, it checks image quality and automatically segments (assembles) the image slices into a single 3D volume image. It then electronically isolates the brain from the skull and its membranes, segregates grey matter from white (connective nerve tissue), identifies and quantifies all regions of the brain with great accuracy, and delivers a statistical report including colorized images – all in about 8.5 minutes of processing on Brewer’s iMac.<br />
<br />
NeuroQuant, which is FDA-approved, was launched by CorTechs Labs, Inc. in September 2007 at the Society for Neuroscience meeting.<br />
<br />
“We primarily used Macs for development,” says CorTechs CEO Michael Smith. “We used OsiriX, an open-source DICOM viewer, to review images. When it came time to decide what platform to release it on, we had been demoing it on Macs, and running it internally on Macs, and we were just getting rave reviews, so it seemed like a no-brainer to roll it out on the Mac. It runs on any Mac, and will perform an analysis in well under five minutes on an 8-core Mac Pro. By marrying it to OsiriX, we give our users a really rich visual experience.”<br />
<br />
The most high-profile use of NeuroQuant is for Alzheimer's disease, but it has great potential for the diagnosis of other diseases such as epilepsy, where it may replace the highly invasive examination now in wide use. It is already at work in clinical trials research in the pharma industry.<br />
<br />
“We’re excited about NeuroQuant,” says Smith, “because we think it will not only make a big difference in the clinical assessment of patients with neurodegenerative disorders, but it will also end up being a very important product for our development as a company. Much of that we have to credit to the form factor, and the ease of use and nice experience, that we get by rolling this out on the Apple platform. And the leverage we get by having a tool like OsiriX on that platform has strengths that clearly complement this tool. We’re delighted to be able to offer our customers the ability to use NeuroQuant and OsiriX in a tightly integrated fashion.”<br />
<br />
<b>A Powerful Tool for Clinical Assessment of Patients</b>Brewer, who is both professor and clinician as well as a Mac enthusiast, divides his time between teaching residents at the Neurosciences and Radiology Department in the UCSD Medical Center and heading up the Human Memory Laboratory, a research facility in a nearby professional center. The lab, according to Brewer, is very Mac-ish. “We try to do everything we can on Macs.”<br />
<br />
Patients referred to Brewer with mild cognitive impairment receive a seven-minute, full-volume MRI brain scan at the UCSD Radiology Department. DICOM image files from the exam move to the hospital’s PACS system. Brewer pulls them onto his iMac using OsiriX. NeuroQuant also resides on Brewer’s iMac. He sends the DICOM files directly to NeuroQuant for processing.<br />
<br />
The results – colorized images and statistical reports – are now available on the NeuroQuant web-based browser. They tell Brewer the volume of the patient’s hippocampi, and how they compare to those of healthy patients of the same age. After he adds his diagnostic comments, NeuroQuant outputs the report as a PDF for billing and for informing the referring doctor. It also outputs a DICOM-compliant image series that he sends back to the hospital’s PACS server.<br />
<br />
<b>The Bottom Line: Better Care for AD Patients</b>“What we’re trying to do here is bring a brand new concept to practice using NeuroQuant and the Mac platform,” says Brewer. “When doctors attribute memory impairment to AD, they’re usually right – but many times they’re not, and they’re prescribing drugs inappropriately. That’s not a major concern right now, because the drugs we have for AD don’t cause a lot of side effects, other than, say, some mild stomach upset. But the stronger drugs now being developed will have much more serious side effects. You're not going to want to throw those willy-nilly at a patient. We’re saying, let’s get some more objective evidence.<br />
<br />
“That’s what we’re trying to provide with NeuroQuant. Radiologists can look at an MRI and see atrophy that looks like AD. But by the time they can see that, the disease is pretty severe, and we can already tell clinically that the person has AD. We’re trying to push the diagnosis back in time to where we can make an intervention such as enrolling them in a clinical medication trial and sparing as many nerve cells as possible.<br />
<br />
“You're not usually going to bring those cells back from death. If a person’s already demented when you intervene, they're likely to stay demented. But if we can use NeuroQuant to catch AD at the mild cognitive impairment stage, where the worst problem they have is losing keys or forgetting names, we can keep it from getting worse. That’s the stage where we’d like to diagnose this stuff.”<br />
<br />
Although Brewer has not actively sought outside referrals for his clinical work, he’s getting AD patient referrals every week for the exam. And he is also breaking ground in research: he recently completed a study of 269 patients with mild cognitive impairment with the help of just two post-doctoral fellows – an impossibility without NeuroQuant and his iMac.<br />
<br />
<br />
<b>At A Glance</b> Professor Jim Brewer of UCSD operates a neurology practice at the Human Memory Laboratory in La Jolla, California. Like other neurologists, he sought a practical way to measure shrinkage of the hippocampus, the memory gateway to the brain, to gain objective evidence of early Alzheimer's disease as the cause of mild memory loss. Existing methods required manually tracing the organ on 256 image slices from an MRI brain scan – a process that can take 100 hours.<br />
<br />
Brewer’s practice became a beta site for NeuroQuant, a Mac-based image analysis system that processes MRI DICOM brain-scan images, quantifies the volumes of all regions of the brain, and provides statistical data showing hippocampus size for healthy patients of the same age. Brewer runs NeuroQuant on an iMac, along with OsiriX, an open-source DICOM viewer and PACS workstation. Pulling a patient’s DICOM files from the hospital PACS, Brewer can quantify hippocampus size in about 8.5 minutes. MRI volume navigation adds accuracy to second-look breast ultrasoundtag:community.radrounds.com,2009-12-28:1791588:Topic:597592009-12-28T21:07:39.844ZRadNet Management, Inc.https://community.radrounds.com/profile/RadNetManagementInc
MRI volume navigation adds accuracy to second-look breast ultrasound<br />
By Brian Casey<br />
AuntMinnie.com staff writer<br />
November 11, 2009<br />
<br />
Sunday, November 29 | 12:30 p.m.-1:30 p.m. | LL-BR4062-B07 | Lakeside Learning Center<br />
Second-look ultrasound has become a useful technique for gaining additional information on lesions first identified on breast MRI scans. In this Sunday afternoon presentation, Italian researchers go a step further by adding a magnetic-based volume navigation system that enables the…
MRI volume navigation adds accuracy to second-look breast ultrasound<br />
By Brian Casey<br />
AuntMinnie.com staff writer<br />
November 11, 2009<br />
<br />
Sunday, November 29 | 12:30 p.m.-1:30 p.m. | LL-BR4062-B07 | Lakeside Learning Center<br />
Second-look ultrasound has become a useful technique for gaining additional information on lesions first identified on breast MRI scans. In this Sunday afternoon presentation, Italian researchers go a step further by adding a magnetic-based volume navigation system that enables the fusion of breast ultrasound and MRI scans.<br />
<br />
Researchers from San Giovanni di Dio General Hospital in Gorizia examined seven patients in this small study, and compared the accuracy of second-look ultrasound both with and without MRI volume navigation and fusion imaging.<br />
<br />
Patients were first examined on a 1.5-tesla MRI scanner (Achieva, Philips Healthcare, Andover, MA) using a T1-weighted THRIVE sequence, while second-look ultrasound (Logiq E9, GE Healthcare, Chalfont St. Giles, U.K.) was also performed.<br />
<br />
The volume navigation technique (VNav, GE Healthcare) involved the use of dual electromagnetic systems that consisted of a transmitter placed close to the patient and two small magnetic receivers attached to the ultrasound scanner probe's bracket.<br />
<br />
Breast MRI scans revealed eight additional lesions in the patients. Second-look ultrasound with the magnetic navigation technique detected seven of eight lesions (87%), versus two of eight (25%) without it. The experimental procedure's sensitivity was 75%, versus 50% for the control group, although it had a lower specificity (50% versus 60%).<br />
<br />
The study indicates that the volume navigation technique could help reduce the number of biopsies of suspicious lesions detected on breast MRI scans, according to presenter Dr. Alfonso Fausto. The study's ramifications are limited by the small patient size, however, according to the presenters. Targeted breast US stands on its own for women under 30tag:community.radrounds.com,2009-12-28:1791588:Topic:597572009-12-28T21:04:36.287ZRadNet Management, Inc.https://community.radrounds.com/profile/RadNetManagementInc
Targeted breast US stands on its own for women under 30<br />
By Edward Susman<br />
December 24, 2009<br />
<br />
Targeted breast ultrasound can be used on its own, without the need for mammography, in following up suspicious areas of concern in women younger than 30, but the jury is still out on whether mammography is needed for women ages 30 to 39, according to a pair of presentations at the RSNA meeting in Chicago earlier this month.<br />
<br />
Although breast ultrasound is already indicated for women younger than 30 with…
Targeted breast US stands on its own for women under 30<br />
By Edward Susman<br />
December 24, 2009<br />
<br />
Targeted breast ultrasound can be used on its own, without the need for mammography, in following up suspicious areas of concern in women younger than 30, but the jury is still out on whether mammography is needed for women ages 30 to 39, according to a pair of presentations at the RSNA meeting in Chicago earlier this month.<br />
<br />
Although breast ultrasound is already indicated for women younger than 30 with suspicious breast findings, outcomes data are lacking for women in this age group. Another important question is whether mammography should also be performed in these patients.<br />
<br />
Seeking to answer these questions was a research team led by Dr. Constance Lehman, Ph.D., from the University of Washington in Seattle. The group examined a cohort of 830 women younger than 30 who underwent ultrasound evaluation of suspicious lesions. The group received 1,123 ultrasound studies, and 1,091 lesions were detected.<br />
<br />
Biopsy was recommended in 174 patients and actually performed in 168. Of those, three patients were diagnosed with cancer, for a positive biopsy rate of 1.8%, and all three cancers were detected and identified by ultrasound. No other lesions were cancer, and all of the nonmalignancies were graded as BI-RADS 1-3, indicating they were probably not malignant.<br />
<br />
"We found no malignancy in any patient with a negative, benign, or probably benign ultrasound finding," Lehman said.<br />
<br />
The overall incidence of cancer in the women younger than 30 is low (0.4%), and the biopsy yield is also low, the researchers noted. This indicates that surveillance with ultrasound might be preferred over biopsy in these very young patients.<br />
<br />
"Ultrasound is highly sensitive in this setting [100%], supporting its use as the primary imaging modality," she said.<br />
<br />
The researchers also conducted a second study that examined the use of ultrasound in women ages 30 to 39 to determine whether mammography was needed in this older patient population as well.<br />
<br />
Over a four-year study period, the researchers pulled 1,327 cases representing 1,032 patients. In all, 98% of cases were benign (1,301/1,327) and 2% were malignant (26/1,327). All of the cancers at the site of concern were identified by ultrasound and none by mammography.<br />
<br />
Ultrasound turned in a sensitivity rate at the site of concern of 100%, compared with 64% for mammography, and ultrasound's specificity was 89%, compared with 94% for mammography. Mammography use resulted in the detection of one additional cancer in an asymptomatic area of the breast in a 32-year-old found to have a BRCA2 mutation.<br />
<br />
The authors concluded that imaging is warranted in women 30 to 39 who present with focal signs or symptoms of cancer due to the small but real risk of malignancy. Ultrasound shows high sensitivity in this patient population, while the added value of mammography is less clear and warrants additional research.<br />
<br />
The studies indicate that breast physicians can be more comfortable with ultrasound's findings in guiding additional workup, said Dr. Joseph Tashjian, president of St. Paul Radiology in Minnesota. Tashjian moderated an RSNA press briefing at which the results were presented.<br />
<br />
"Many women of this age have 'lumpy' breasts, which is different than a 'lump' in the breast," Tashjian said. "Dr. Lehman's study shows that we can be comfortable in starting out diagnostic workup with ultrasound in these women. We have had the same experience as Dr. Lehman with ultrasound. We find it very reliably answers the question as to whether the lesion is cancer or normal breast tissue."<br />
<br />
By Ed Susman<br />
AuntMinnie.com contributing writer<br />
December 24, 2009 Clinical Utility of PET/CT in Lymphomatag:community.radrounds.com,2009-12-28:1791588:Topic:597542009-12-28T20:52:26.283ZRadNet Management, Inc.https://community.radrounds.com/profile/RadNetManagementInc
Clinical Utility of PET/CT in Lymphoma<br />
Carmel G. Cronin1, Ronan Swords2, Mylene T. Truong3, Chitra Viswanathan3, Eric Rohren3, Francis J. Giles2, Michael O'Dwyer4 and John F. Bruzzi1<br />
1 Department of Radiology, University College Hospital Galway, Galway University Hospitals, Newcastle Rd., Galway, Ireland.<br />
2 Division of Hematology and Medical Oncology, Cancer Therapy and Research Center, Institute for Drug Development, University of Texas Health Science Center, San Antonio, TX.<br />
3 Department of…
Clinical Utility of PET/CT in Lymphoma<br />
Carmel G. Cronin1, Ronan Swords2, Mylene T. Truong3, Chitra Viswanathan3, Eric Rohren3, Francis J. Giles2, Michael O'Dwyer4 and John F. Bruzzi1<br />
1 Department of Radiology, University College Hospital Galway, Galway University Hospitals, Newcastle Rd., Galway, Ireland.<br />
2 Division of Hematology and Medical Oncology, Cancer Therapy and Research Center, Institute for Drug Development, University of Texas Health Science Center, San Antonio, TX.<br />
3 Department of Diagnostic Imaging, M. D. Anderson Cancer Center, Houston, TX<br />
<br />
<br />
Source: <a href="http://www.ajronline.org/cgi/content/abstract/194/1/W91?rss=1">http://www.ajronline.org/cgi/content/abstract/194/1/W91?rss=1</a><br />
4 Department of Hematology, University College Hospital Galway, Galway University Hospitals, Galway, Ireland.<br />
<br />
OBJECTIVE. The purpose of this review is to assist interpreting radiologists in becoming familiar with the role of PET/CT in baseline staging and therapeutic response assessment in the management of lymphoma, in becoming aware of imaging pitfalls, and in understanding the natural behavior of lymphoma and the therapeutic options.<br />
<br />
CONCLUSION. Therapeutic strategies for the management of lymphoma are constantly being refined to improve long-term survival with the lowest risk of toxicity to the patient. PET/CT is accurate for baseline staging and yields important prognostic information for determining the most appropriate initial treatment. Used for evaluation of treatment response, PET/CT can depict residual viable malignant lesions with greater accuracy than can other imaging techniques. The findings thereby influence decisions about the need for additional or alternative treatment. CT Angiography in Aneurysmal Subarachnoid Hemorrhagetag:community.radrounds.com,2009-12-28:1791588:Topic:597532009-12-28T20:51:06.630ZRadNet Management, Inc.https://community.radrounds.com/profile/RadNetManagementInc
Should CT Angiography Be Routinely Used in Patients Suspected of Having Aneurysmal Subarachnoid Hemorrhage? No!<br />
<a href="http://radiology.rsna.org/content/254/1/314.short?rss=1">http://radiology.rsna.org/content/254/1/314.short?rss=1</a>
Should CT Angiography Be Routinely Used in Patients Suspected of Having Aneurysmal Subarachnoid Hemorrhage? No!<br />
<a href="http://radiology.rsna.org/content/254/1/314.short?rss=1">http://radiology.rsna.org/content/254/1/314.short?rss=1</a> CT and MRI of paediatric Crohn diseasetag:community.radrounds.com,2009-12-28:1791588:Topic:597492009-12-28T20:39:08.896ZRadNet Management, Inc.https://community.radrounds.com/profile/RadNetManagementInc
Over the past two decades there has been considerable evolution in cross-sectional imaging modalities for the evaluation of Crohn disease (CD) in children. CT and MRI have contributed to conventional techniques so that now radiology has an even greater role in the management of CD, monitoring disease progression and detecting complications. The role of CT and MRI, their limitations, and the various imaging features that the radiologist should be aware of are discussed in this review.
Over the past two decades there has been considerable evolution in cross-sectional imaging modalities for the evaluation of Crohn disease (CD) in children. CT and MRI have contributed to conventional techniques so that now radiology has an even greater role in the management of CD, monitoring disease progression and detecting complications. The role of CT and MRI, their limitations, and the various imaging features that the radiologist should be aware of are discussed in this review. Researchers Identify Possible Imaging Method To Stratify Breast Cancer Without Biopsytag:community.radrounds.com,2009-12-28:1791588:Topic:597452009-12-28T20:20:56.643ZRadNet Management, Inc.https://community.radrounds.com/profile/RadNetManagementInc
Scientists from the Kimmel Cancer Center at Jefferson have discovered a possible way for malignant breast tumors to be identified, without the need for a biopsy. The findings were published online ahead of print in the Journal of Nuclear Medicine.<br />
<br />
Current imaging modalities miss up to 30% of breast cancers and cannot distinguish malignant tumors from benign tumors, thus requiring invasive biopsies. Approximately 5.6 million biopsies performed in the United States find only benign lesions.…
Scientists from the Kimmel Cancer Center at Jefferson have discovered a possible way for malignant breast tumors to be identified, without the need for a biopsy. The findings were published online ahead of print in the Journal of Nuclear Medicine.<br />
<br />
Current imaging modalities miss up to 30% of breast cancers and cannot distinguish malignant tumors from benign tumors, thus requiring invasive biopsies. Approximately 5.6 million biopsies performed in the United States find only benign lesions. These biopsies cause substantial stress for the patients and have significantly high costs.<br />
<br />
"The challenge has been to develop an imaging agent that will target a specific, fingerprint biomarker that visualizes malignant breast lesions early and reliably," said Mathew Thakur, Ph.D., professor of Radiology at Jefferson Medical College of Thomas Jefferson University and director of Radiopharmaceutical Research and Nuclear Medicine Research.<br />
<br />
Dr. Thakur and colleagues studied an agent called 64Cu-TP3805, which is used to evaluate tumors via PET imaging. 64Cu-TP3805 detects breast cancer by finding a biomarker called VPAC1, which is overexpressed as the tumor develops.<br />
<br />
The researchers compared the images using that agent with images using the "gold standard" imaging agent, 18F-FDG. They used MMTVneu mice, which are mice that develop breast tumors spontaneously, like humans. The mice first received a PET scan using the 18F-FDG. Then they received a CT scan, and then they received another PET scan using 64Cu-TP3805. Ten tumors were detected on the mice. Four tumors were detected using both 18F-FDG and 64Cu-TP3805, and four additional tumors were found with 64Cu-TP3805 only. All eight of these tumors overexpressed the VPAC1 oncogene on tumor cells and were malignant by histology. The remaining two tumors were benign and were detected only with 18F-FDG. They did not express the VPAC1 oncogene, and thus were not detected by the 64Cu-TP3805. "If this ability of 64Cu-TP3805 holds up in humans, then in the future, PET scans with 64Cu-TP3805 will significantly contribute to the management of breast cancer," Dr. Thakur said. Other Jefferson researchers involved in the study include Devakumar Devadhas, Ph.D.; Kaijun Zhang, Ph.D.; Richard G. Pestell, M.D., Ph.D.; Chenguang Wang, Ph.D.; Peter McCue, M.D.; and Eric Wickstrom, Ph.D.<br />
<br />
Source<br />
Thomas Jefferson University<br />
--------------------------------------------------------------------------------<br />
<br />
Article URL: <a href="http://www.medicalnewstoday.com/articles/174335.php">http://www.medicalnewstoday.com/articles/174335.php</a> Radiology leaders react cautiously to Obama’s healthcare planstag:community.radrounds.com,2009-12-28:1791588:Topic:597422009-12-28T20:17:05.357ZRadNet Management, Inc.https://community.radrounds.com/profile/RadNetManagementInc
Radiology leaders react cautiously to Obama’s healthcare plans...<br />
<a href="http://www.diagnosticimaging.com/news/display/article/113619/1452528?verify=0">http://www.diagnosticimaging.com/news/display/article/113619/1452528?verify=0</a>
Radiology leaders react cautiously to Obama’s healthcare plans...<br />
<a href="http://www.diagnosticimaging.com/news/display/article/113619/1452528?verify=0">http://www.diagnosticimaging.com/news/display/article/113619/1452528?verify=0</a>